Flu and COVID-19 infections rise ahead of holiday gatherings

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because…

Some hospitals have reactivated mask mandates in response to a rise in COVID-19 cases and influenza respiratory infections, although the current increase is minimal compared to the spikes seen during the pandemic. (iStock) BACK TO MASKING – Some hospitals in New York and several other states have reinstated mask mandates. Here’s what doctors have to…

Shares of Walgreens closed 5% lower on Thursday after the company reported fiscal first-quarter adjusted earnings and revenue that topped expectations, but cut its quarterly dividend nearly in half.  The retail pharmacy giant slashed its dividend to 25 cents per share from 48 cents per share to “strengthen [its] long-term balance sheet and cash position,” CEO…

George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market.  The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. …

Close to 20 million people are likely to have died during the last three years, says the WHO.

Business & FinanceDealsHealth 14 July 2023, 5:43 pm 1 minute MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition. Market Impact MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday,…